This finding is supported by a recent meta-analysis showing that T2DM patients carrying CYP2C9*2 had a higher risk of hypoglycemic episodes due to reduced metabolic activity, ultimately compromising SU efficacy [54]. The gene discussed is CYP2C9; the disease is type 2 diabetes mellitus.